Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13. Dezember 2024 07:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
14. November 2024 16:05 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter...
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
06. November 2024 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
22. Oktober 2024 16:01 ET
|
Genelux Corporation
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
09. Oktober 2024 16:15 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
03. September 2024 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14. August 2024 16:05 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
30. Juli 2024 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
24. Mai 2024 08:00 ET
|
Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
23. Mai 2024 16:01 ET
|
Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants